Sandoz

News
Novartis-AU-HQ

Novartis sells parts of Sandoz for $1bn

After disappointing sales, Novartis trades in the Sandoz US dermatology business and generic oral solids portfolio to Aurobindo Pharma, in a deal worth nearly $1 billion.

News
AbbVie's Humira (adalimumab)

Fourth Humira biosimilar set for EU approval

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim, Sams

News
AbbVie's Humira (adalimumab)

Novartis files Humira biosimilar in US

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires.